Mental health continues to be a growing global concern. This firm is expanding its lineup by adding DMT-psychedelics for patient care.
Neuroscience firm Small Pharma Inc. (TSXV: DMT) focuses on psychedelic-assisted therapies for mental health conditions. The company announced in its press release the research and development updates on two N,N-dimethyltryptamine "DMT" based candidates.
The firm’s pipeline of short duration psychedelics can potentially provide effective, practical and accessible for a range of mental health conditions. Two additional trials have been added to SPL026’s development program while the SPL028 program moves towards a Phase I clinical trial in H2 2022.
As the markets continued to slide over the situation in Ukraine, shares were trading down at $0.235.
